CompBrief BY VELARION

Companies Avenue Therapeutics, Inc

Avenue Therapeutics CEO salary & total pay, FY2025: $447K

Avenue Therapeutics (ATXI) CEO salary, fiscal 2025: Alexandra MacLean was paid a salary of $420,000 and $447,307 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Avenue Therapeutics, Inc’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Alexandra MacLean's complete compensation dossier

A PDF and a CSV sent to your email: Alexandra MacLean's pay in every fiscal year Avenue Therapeutics, Inc reported it, line by line, with Alexandra MacLean's equity grants and Avenue Therapeutics, Inc's disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$447,307CEO Alexandra MacLean · source
Say-on-pay support98.34%Latest vote · source

CEO pay, last three years

  • $1,213,200FY2023
  • $840,100FY2024
  • $447,307FY2025

CEO total pay was $447,307 in fiscal 2025, down from $840,100 in fiscal 2024.

FY2025: salary $420,000 · bonus $0 · stock awards $13,307 · option awards $0

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Avenue Therapeutics, Inc in fiscal 2025?
As disclosed, Alexandra MacLean (Chief Executive Officer) was the highest-paid executive at Avenue Therapeutics, Inc in fiscal 2025, with total compensation of $447,307.
How did shareholders vote on Avenue Therapeutics, Inc's executive compensation?
As disclosed, 98.34% of shareholders supported Avenue Therapeutics, Inc's executive compensation in the latest say-on-pay vote.
How much does Avenue Therapeutics, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Avenue Therapeutics, Inc reported total board compensation of $270,000 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Alexandra MacLean$420,000$0$13,307$0$0$0$14,000$447,307
Chief Executive Officer
David Jin007,98400007,984
Interim Chief Financial Officer and Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Alexandra MacLean$447,307$840,100$1,213,200↓ −392,793
David Jin7,984155,350260,000↓ −147,366

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company provides compensation to its named executive officers based on at-will employment terms, with the CEO eligible for a discretionary annual bonus and equity awards granted primarily through subsidiary plans prior to acquisition. The compensation structure relies on base salary, discretionary bonuses, and equity incentives such as RSUs and options, with no formal written employment contracts in place.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
David JinRSU———266,147—$7,984
Alexandra MacLeanRSU———443,578—13,307

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
David Jin$7,984$0$00.0%
Alexandra MacLean13,307000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Alexandra MacLeanOption8,0042,66485.5—
Alexandra MacLeanRSU—42,500—28,909
David JinOption2,50083485.5—
David JinRSU—16,250—11,053
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Jay Kranzler, M.D., PhDNot independent · Board Chair$60,000—$0—$50,000$110,000
Neil HerskowitzIndependent60,000—0—060,000
Curtis OltmansIndependent50,000—0—050,000
Faith CharlesIndependent50,000—0—050,000
Lindsay A. Rosenwald, M.DNot independent0—0—0—

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$220,000
Equity awards (grant-date value)$0
All other compensation$50,000
Total cost of the board$270,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Avenue Therapeutics as a peer

Companies that benchmark against ATXI

No companies currently name ATXI as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Avenue Therapeutics, Inc2025Alexandra MacLean$420,000$13,307$0$0$447,307

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-12-30—————
20242024-06-24—————
20232023-06-229,541,965128,47232,59798.34%Passed
20212021-12-16—————
20202020-06-16—————
20192019-06-19—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20252025-12-30—a
20242024-06-24—b
20232023-06-2298.34%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Approved under the standard stated in the filing — “The affirmative vote of a majority of the shares present, virtually at the Annual Meeting or by proxy, and entitled to vote at the Annual Meeting is required to approve the compensation of our named executive officers. || Abstentions will have the same effect as a vote "AGAINST" this proposal.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

No insider equity transactions reported since the proxy statement.

Sources (16 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Alexandra MacLean. 10-K, filed 2026-03-30. Section “Executive Compensation” · page 71. As printed: 447,307. View filing ↗
  • Section 01, David Jin. 10-K, filed 2026-03-30. Section “Executive Compensation” · page 71. As printed: 7,984. View filing ↗
  • Section 03, David Jin RSU. DEF 14A, filed 2026-03-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Alexandra MacLean RSU. DEF 14A, filed 2026-03-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 08, Jay Kranzler, M.D., PhD. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: 110,000. View filing ↗
  • Section 08, Neil Herskowitz. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: 60,000. View filing ↗
  • Section 08, Curtis Oltmans. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: 50,000. View filing ↗
  • Section 08, Faith Charles. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: 50,000. View filing ↗
  • Section 08, Lindsay A. Rosenwald, M.D. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: —. View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-12-31. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-26. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-26. Item 5.07 · say-on-pay result. As reported: 98.34% (votes for as printed: 9,541,965). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 220,000 + equity 0 + all other 50,000 = 270,000, summed across the director compensation table rows.
  • Avenue Therapeutics, Inc (subject), Section 10b CEO total. 10-K, filed 2026-03-30. CEO total compensation as printed in Avenue Therapeutics, Inc's own proxy. As printed: 447,307. View filing ↗
Get the full report — $299